SCHEMBL4438933

SCHEMBL4438933

NC1(N)C=CC(C=Cc2ccccc2)=CC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.39
CYP19A1 P11511 2/20 0.39
MAOA P21397 2/20 0.39
CHAT P28329 2/20 0.36
NFE2L2 Q16236 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM1A O60341 2/20 0.34
TTR P02766 1/20 0.34
ALOX5 P09917 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
GRM4 Q14833 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34
CMA1 P23946 1/20 0.33
TRPA1 O75762 2/20 0.32
RELA Q04206 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27514626 0.98 MAOB (0.38) MAOBCYP19A1MAOACHATNFE2L2
Hydrochloric Acid SCHEMBL12003783 0.98 MAOB (0.38) MAOBCYP19A1MAOACHATNFE2L2
Pyrophosphoric Acid SCHEMBL9791300 0.86 HDAC1 (0.32) MAOBCYP19A1MAOACMA1
SCHEMBL9344854 0.83 MAOB (0.37) MAOBCYP19A1MAOACHATNFE2L2
SCHEMBL27693757 0.83 MAOB (0.37) MAOBCYP19A1MAOACHATNFE2L2
SCHEMBL6837817 0.81 CHAT (0.35) MAOBCYP19A1MAOACHATNFE2L2
SCHEMBL4595773 0.81 CHAT (0.39) MAOBCYP19A1MAOACHATNFE2L2
SCHEMBL30781477 0.81 CHAT (0.39) MAOBCYP19A1MAOACHATNFE2L2
SCHEMBL28484538 0.81 CHAT (0.39) MAOBCYP19A1MAOACHATNFE2L2
SCHEMBL28697334 0.81 CHAT (0.35) MAOBCYP19A1MAOACHATNFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114671819-A Continuous feeding type fluorescent whitening agent production method 北京奥得赛化学有限公司 2022-06-28 CN claimed
US-10336715-B2 Phosphoric acid loaded covalent organic framework and a process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-07-02 US claimed
CN-109704979-A 4,4- diaminostilbene, the method for 1- dianthraquinone are efficiently prepared using Bronsted acidic functionalized ionic liquid 山东宇虹新颜料股份有限公司 2019-05-03 CN claimed
US-20170362190-A1 Phosphoric Acid Loaded Covalent Organic Framework And A Process For The Preparation Thereof COUNCIL SCIENT IND RES (IN) 2017-12-21 US claimed
US-9758493-B2 Phosphoric acid loaded covalent organic framework and a process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-09-12 US claimed
US-20150299147-A1 Phosphoric Acid Loaded Covalent Organic Framework And A Process For The Preparation Thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-10-22 US claimed
US-5342904-A Polymer modified adducts of epoxy resins and active hydrogen containing compounds containing mesogenic moieties THE DOW CHEMICAL COMPANY (US) 1994-08-30 US claimed
US-12486276-B2 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer PYRAMID BIOSCIENCES, INC. (US) 2025-12-02 US disclosed
CN-120082001-A High-strength low-temperature-resistant organic silicon polyurethane resin and preparation method thereof 烟台先进材料与绿色制造山东省实验室 2025-06-03 CN disclosed
EP-3270884-B1 METHOD OF MAKING AN OPTICALLY-ACTIVATED SYSTEM ELC MAN LLC (US) 2025-04-30 EP disclosed
US-20240246976-A1 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER PYRAMID BIOSCIENCES INC (US) 2024-07-25 US disclosed
CN-117654516-A Modified alumina carrier hydrogenation catalyst and preparation method thereof 上海贝菱化工科技有限公司 2024-03-08 CN disclosed
WO-2022138639-A1 OPHTHALMIC COMPOSITION OF RIFAMYCIN, AND USE THEREOF ビーエヌシー コリア カンパニー,リミテッド 2022-06-30 WO disclosed
EP-0342637-A2 Silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1989-11-23 EP disclosed
EP-0324476-A2 Silver halide color photosensitive materials FUJI PHOTO FILM CO., LTD. (JP) 1989-07-19 EP disclosed
EP-0312984-A2 Method for processing silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1989-04-26 EP disclosed
EP-0308706-A1 Method for processing a silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1989-03-29 EP disclosed
EP-0298321-A2 Silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1989-01-11 EP disclosed
EP-0295716-A2 Process for the formation of color image and band stop filter used therefor FUJI PHOTO FILM CO., LTD. (JP) 1988-12-21 EP disclosed
US-4546068-A AROMATIC AMINE DEVELOPER, MANANESE AND OR CERIUM SALT, DIPHOSPHONIC ACID SEQUESTERING AGENT KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1985-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486276-B2 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer DTYMK, DCK, MAP3K9 MAOB 4169/4885CYP19A1 2326/4885MAOA 4285/4885
US-20240246976-A1 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER DTYMK, DCK, MAP3K9 MAOB 4169/4885CYP19A1 2326/4885MAOA 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.